233 related articles for article (PubMed ID: 29672587)
1. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.
Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J
PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587
[TBL] [Abstract][Full Text] [Related]
2. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H; Hideshima T; Fulciniti M; Lutz RJ; Yasui H; Okawa Y; Kiziltepe T; Vallet S; Pozzi S; Santo L; Perrone G; Tai YT; Cirstea D; Raje NS; Uherek C; Dälken B; Aigner S; Osterroth F; Munshi N; Richardson P; Anderson KC
Clin Cancer Res; 2009 Jun; 15(12):4028-37. PubMed ID: 19509164
[TBL] [Abstract][Full Text] [Related]
3. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
4. Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation.
Debaene F; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
Anal Chem; 2013 Oct; 85(20):9785-92. PubMed ID: 24007193
[TBL] [Abstract][Full Text] [Related]
5. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
6. Enlarging the repertoire of therapeutic monoclonal antibodies platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies.
Yang X; Ambrogelly A
Curr Opin Biotechnol; 2014 Dec; 30():225-9. PubMed ID: 25254943
[TBL] [Abstract][Full Text] [Related]
7. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
8. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
9. The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation.
Silva JP; Vetterlein O; Jose J; Peters S; Kirby H
J Biol Chem; 2015 Feb; 290(9):5462-9. PubMed ID: 25568323
[TBL] [Abstract][Full Text] [Related]
10. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys.
Stubenrauch K; Wessels U; Regula JT; Kettenberger H; Schleypen J; Kohnert U
Drug Metab Dispos; 2010 Jan; 38(1):84-91. PubMed ID: 19850673
[TBL] [Abstract][Full Text] [Related]
11. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
12. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
[TBL] [Abstract][Full Text] [Related]
13. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.
McDonagh CF; Kim KM; Turcott E; Brown LL; Westendorf L; Feist T; Sussman D; Stone I; Anderson M; Miyamoto J; Lyon R; Alley SC; Gerber HP; Carter PJ
Mol Cancer Ther; 2008 Sep; 7(9):2913-23. PubMed ID: 18790772
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4.
Shapiro RI; Plavina T; Schlain BR; Pepinsky RB; Garber EA; Jarpe M; Hochman PS; Wehner NG; Bard F; Motter R; Yednock TA; Taylor FR
J Pharm Biomed Anal; 2011 Apr; 55(1):168-75. PubMed ID: 21300512
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
[TBL] [Abstract][Full Text] [Related]
16. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
18. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
Salomon PL; Singh R
Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
[TBL] [Abstract][Full Text] [Related]
19. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
